GBA1 and Parkinson disease: It is believed that with the emergence of novel therapies and technologies, such as GCase modulators, cell treatment, antisense oligonucleotides, microRNAs, ncRNAs, and CRISPR-Cas9, among others, there will be new opportunities for the treatment of GBA1-PD [38, 107, 110, 252, 268–271].